We use cookies for analytics and ads to improve your experience. You can accept or decline. See our Privacy Policy.
Unlisted shares are illiquid and carry higher risk than listed securities. Prices are indicative, not live. Read the risk disclosure.

Valuation
Investment Thesis
Medexport India Limited is a small, unlisted pharmaceutical export company with very limited public information. While India's pharmaceutical export sector has strong secular growth drivers, the absence of corporate details, website, and financial disclosures makes this company very difficult to evaluate. Investors should exercise extreme caution and conduct thorough due diligence via MCA filings before considering any investment.
Pros
Cons
Business Segments
Medical / Pharmaceutical Exports
Export of pharmaceutical products or medical equipment; India-based medical export company.
Revenue Model
Medexport India Limited generates revenue through the export of pharmaceutical products including generic medicines and formulations to international buyers. Revenue is earned on per-shipment or contract basis with international pharma distributors, government procurement agencies, and healthcare institutions in target export markets.
Detailed Analysis
Growth Plans
India's pharmaceutical export sector growing driven by global demand for affordable generic medicines
Government schemes like Production Linked Incentive (PLI) for pharma supporting export-oriented manufacturers
Increasing global demand for Indian-manufactured APIs and formulations
Industry Tailwinds
India's pharmaceutical export sector growing driven by global demand for affordable generic medicines
Recent Developments
No press releases, news coverage, or regulatory announcements found for this company in the public domain.
Comparable Companies
SUNPHARMA · ~₹3,50,000 Cr
Frequently Asked Questions
About Medexport India
Medexport India Limited is an Indian pharmaceutical export company engaged in the export of medicines, active pharmaceutical ingredients (APIs), and healthcare products to international markets. India is the world's pharmacy, supplying approximately 60% of global vaccine demand and being a leading exporter of generic medicines to over 200 countries. Medexport India operates in the pharmaceutical export value chain, either as a trader/exporter of finished formulations, an API exporter, or a combination of both. Indian pharmaceutical exporters benefit from the country's established manufacturing base, low production costs, and globally recognised generic medicine expertise. The company's target markets may include regulated markets (US, Europe, UK, Canada, Australia) requiring stringent regulatory approvals, or semi-regulated markets (Africa, Southeast Asia, Latin America) that are served by Indian generic manufacturers. Pharmaceutical exporters earn revenue through direct product sales to overseas distributors, hospitals, and government procurement agencies. Given limited public data for Medexport India Limited, specific financial metrics including revenue scale, product portfolio, and geographic markets are not publicly confirmed. The company operates in a sector with strong fundamental tailwinds given India's dominant position in global generic medicine supply.
Key Milestones
Medexport India Limited — medical/pharmaceutical export company; minimal public data available
Common questions about unlisted shares
You buy from and sell to the wisefolio desk — shares route through the desk's demat, money-in before shares-out.
You enquire
· Takes 2 minutesTell us the company and quantity you want. Share your demat details so we can settle directly into your account.
We source & quote
· Typically within 1 business dayOur desk sources the shares and comes back with a firm price and an allocation for the quantity available.
You accept the allocation
· Quote valid for 3 daysReview the price, quantity and total. Accept to lock the allocation. The quote is valid for a short window before it needs re-pricing.
You transfer the funds
· Pay within 2 days of acceptingPay by direct bank transfer to the desk's published account — never to a personal account. We confirm receipt and begin the transfer.
Shares reach your demat
· Usually credited within 2–3 business daysOnce payment is verified, the shares are transferred from the desk's demat into yours, and you receive a transfer confirmation.
A principal desk for unlisted & pre-IPO shares — you transact with us, not a stranger.
You enquire
Takes 2 minutes
We source & quote
Typically within 1 business day
You accept the allocation
Quote valid for 3 days
You transfer the funds
Pay within 2 days of accepting
Shares reach your demat
Usually credited within 2–3 business days
Unlisted shares are illiquid and carry higher risk. Pricing is indicative, not live, and these are private off-market transactions with no exchange settlement guarantee. Read the full risk disclosure.
Government schemes like Production Linked Incentive (PLI) for pharma supporting export-oriented manufacturers
Increasing global demand for Indian-manufactured APIs and formulations
Industry Headwinds
Regulatory bans or quality alerts in destination markets disrupting export revenue
Competition from larger, well-capitalised Indian pharma exporters
Currency volatility impacting export profitability
Pharmaceutical exporters must comply with quality standards of importing countries; non-compliance can lead to product bans, recalls, or loss of export licenses
Source: Regulatory Filings
No CIN, ISIN, or corporate website found; extremely limited disclosures make financial health assessment impossible without MCA filings
Source: Media Reports / Public Records
Pharmaceutical export market is highly competitive with large Indian players like Sun Pharma, Cipla, Dr. Reddy's, and Aurobindo having dominant export franchises
Source: AlphaHub Research
Export-oriented businesses face exchange rate risk on foreign currency receivables; INR appreciation reduces profitability
Source: Media Reports / Public Records
Unlisted status makes it extremely difficult to exit investments; shares are traded only in informal pre-IPO or grey markets
Source: Media Reports / Public Records
Pharmaceutical exporters must comply with quality standards of importing countries; non-compliance can lead to product bans, recalls, or loss of export licenses
No CIN, ISIN, or corporate website found; extremely limited disclosures make financial health assessment impossible without MCA filings
Pharmaceutical export market is highly competitive with large Indian players like Sun Pharma, Cipla, Dr. Reddy's, and Aurobindo having dominant export franchises
Export-oriented businesses face exchange rate risk on foreign currency receivables; INR appreciation reduces profitability
Unlisted status makes it extremely difficult to exit investments; shares are traded only in informal pre-IPO or grey markets
AUROPHARMA · ~₹50,000 Cr
CIPLA · ~₹1,20,000 Cr
Be the first to discuss Medexport India — share your research, ask questions, or compare notes with other investors.